In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
AUTOR(ES)
Vazquez, J A
RESUMO
The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the activities of various antifungals. L-743,872 demonstrated the best activity against azole-susceptible and -resistant strains of C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr and less activity against C. krusei, C. lusitaniae, and C. guilliermondii.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163972Documentos Relacionados
- In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.
- In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
- Restriction fragment length polymorphism analysis of azole-resistant and azole-susceptible Candida albicans strains.
- Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
- In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
